CYTR - CytRx Corporation
| Previous Close | 1.74 |
| Open | 1.68 |
| Bid | 1.53 x 1500 |
| Ask | 1.75 x 700 |
| Day's Range | 1.65 - 1.75 |
| 52 Week Range | 1.43 - 6.00 |
| Volume | 138,554 |
| Avg. Volume | 397,006 |
| Market Cap | 47.664M |
| Beta | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.00 |
- PR Newswire•3 days ago
CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting
LADR-7, LADR-8, LADR-9 and LADR-10 Demonstrate Robust Complete and Partial Responses and Long-Term Antitumor Activity in Melanoma, Lung, Breast, Ovarian, Head and Neck and Renal Cell Cancers Conference ...
- PR Newswire•12 days ago
CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference
Discussion Will Cover Developments with Big Pharma for Strategic Partnerships and Superiority of the LADR™ Platform Over Antibody-Drug Conjugates Conference Call and Webcast to be held on Wednesday, April ...
- Thomson Reuters StreetEvents•24 days ago
Edited Transcript of CYTR earnings conference call or presentation 19-Mar-18 3:00pm GMT
Q4 2017 CytRx Corp Earnings Call
- ACCESSWIRE•24 days ago
Blog Exposure - Loxo Oncology Completed Rolling Submission of NDA to the FDA for Larotrectinib for TRK Fusion Cancer Treatment
Stock Monitor: CytRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Loxo Oncology, Inc. (NASDAQ: LOXO ). If you want ...
- ACCESSWIRE•last month
CytRx Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 19, 2018 / CytRx Corporation (NASDAQ: CYTR ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018 at 11:00 AM Eastern Time. ...
- Associated Press•last month
CytRx reports 4Q loss
The Los Angeles-based company said it had a loss of 16 cents per share. The cancer drug developer posted revenue of $100,000 in the period. For the year, the company reported that its loss narrowed to ...
- PR Newswire•last month
CytRx Reports 2017 Financial Results
Four New LADR™ Candidates with Breakthrough Potential Recently Selected for Advancement Into Investigational New Drug-Enabling Studies Company to Host Conference Call Today at 11:00 am ET (8:00 am PT) ...
- PR Newswire•last month
CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference
LOS ANGELES, March 16, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, Advisor to the Chairman and CEO, will present at the 28th Annual Oppenheimer Healthcare Conference on Wednesday, March 21, 2018 at 3:55 P.M. Eastern Daylight Time at the Westin New York Grand Central in New York, New York.
- PR Newswire•last month
CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials
Supportive Data on All Candidates to be Highlighted in Poster Presentations at the Upcoming American Association for Cancer Research 2018 Annual Meeting Next Month LOS ANGELES , March 15, 2018 /PRNewswire/ ...
- PR Newswire•last month
CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018
LOS ANGELES, March 12, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the full year ended December 31, 2017 on Monday, March 19, 2018. CytRx's executives Steven Kriegsman, Chairman and CEO, and John Caloz, Chief Financial Officer, will hold a conference call and webcast beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on that day to discuss the results. To access the conference call, dial 844-358-6753 (U.S. and Canada) or 216-562-0397 (international callers) and enter the conference ID number: 8178698. A live and archived webcast will be available in the investor relations section of the company's website, www.cytrx.com. A replay of the call and webcast will begin approximately two hours after the live call has ended. To access the replay, dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (international callers) and enter the conference ID number: 8178698.
- PR Newswire•2 months ago
CytRx to Present at the 30th Annual ROTH Conference
LOS ANGELES , March 5, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Company will present ...
- Simply Wall St.•2 months ago
Are Earnings Prospects Improving For Loss-Making CytRx Corporation’s (NASDAQ:CYTR)?
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess CytRx Corporation’s (NASDAQ:CYTR) track record on a highRead More...
- PR Newswire•2 months ago
CytRx Announces Key Addition to Corporate Development Team
LOS ANGELES, March 1, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the engagement of Eric L. Curtis, MBA, to provide strategic counsel for the Company's ongoing programs, including its LADR™ (Linker Activated Drug Release) technology platform and ultra-high potency drug candidates, beginning with proof of concept through clinical development. "CytRx is an exciting story, with a lot of potential for its LADR® technology drug candidates to change the way patients with high unmet needs receive treatment," said Mr. Curtis. "Dr. Kratz, and his world-class team at the discovery lab in Freiberg, Germany have created a valuable discovery engine for the creation of new, proprietary drug candidates that employ a linker to deliver a variety of ultra-high potency cytotoxic payloads, but with the potential for low systemic toxicity.
- PR Newswire•2 months ago
CytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug Candidates
LOS ANGELES, Feb. 28, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced its entry into a definitive agreement with Destum Partners, Inc., a leading strategic advisory firm serving companies in the life sciences industry, to assist in its pharma partnering activities. Destum will be the exclusive advisor to CytRx for the identification of partnership opportunities for CytRx's LADR™ (Linker Activated Drug Release) ultra-high potency drug conjugates. At the upcoming American Association for Cancer Research (AACR) 2018 Annual Meeting, April 14-18, 2018, CytRx will be presenting three posters highlighting significant data relating to the LADR™ drug conjugates, and Destum will be introducing the CytRx team to potential strategic partners.
- PR Newswire•2 months ago
CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
All Three Studies Submitted Were Selected for Poster Presentations LOS ANGELES , Feb. 22, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing ...
- PR Newswire•2 months ago
CytRx Corporation to Present at the 2018 BIO CEO & Investor Conference
LOS ANGELES, Feb. 6, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present at the 2018 BIO CEO & Investor Conference on Monday, February 12th at 10:15 a.m. Eastern Time at the New York Marriott Marquis Hotel. Presentation dates and times, along with any links to potential webcasts for the Roth Conference, will be provided closer to the actual event. The 2018 BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
- PR Newswire•2 months ago
CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma
LOS ANGELES, Feb. 5, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with advanced squamous cell carcinoma (SCC) of either the head and neck or non-small cell lung cancer. This is the second trial conducted by NantCell which will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in certain high unmet need cancer indications. The first trial in pancreatic cancer patients commenced in January 2018. The trial titled "QUILT-3.090: Molecularly Informed Integrated Immunotherapy in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programed Death Ligand 1 (PD-L1) Therapy," (NCT03387111) is a single-center, open-label, Phase 1b/2 clinical trial designed to evaluate the safety and efficacy of several combination therapies, including combinations with aldoxorubicin, in subjects with SCC who have progressed on or after platinum-based chemotherapy and anti-PD1/PD-L1 therapy. This trial is expected to enroll approximately 65 patients. The primary endpoint for the Phase 1b portion of the trial is safety and the primary endpoint for the Phase 2 portion of the trial is objective response rate (ORR) by RECIST.
- ACCESSWIRE•3 months ago
Today’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and CytRx Corporation
NEW YORK , NY / ACCESSWIRE / January 24, 2018 / Inovio was one of the best performing stocks in the market yesterday after the company revealed published data that was encouraging regarding its goal of ...
- PR Newswire•3 months ago
CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer
LOS ANGELES, Jan. 17, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with metastatic pancreatic cancer. The trial will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in metastatic pancreatic cancer patients who have progressed on or following standard-of-care therapy. "NantCell's decision to include aldoxorubicin in this new trial speaks to their commitment to expanding its potential use in combination with immuno-oncology agents and cell-based therapies," said Steven A. Kriegsman, CytRx's Chairman and CEO.
- PR Newswire•4 months ago
CytRx Corporation to Present at Biotech Showcase 2018
LOS ANGELES , Jan. 3, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven ...
- PR Newswire•4 months ago
CytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences
LOS ANGELES , Dec. 7, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its presentation scheduled ...
- PR Newswire•4 months ago
CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR™ Drug Candidates
LOS ANGELES, Dec. 6, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has filed provisional patent applications covering two series of drug candidates from its LADR™ (Linker Activated Drug Release) Technology Platform. The newly filed applications cover compounds, pharmaceutical compositions and methods of use thereof. When granted, these new patents will expand CytRx's intellectual property estate and the Company will own worldwide rights for each.
- PR Newswire•5 months ago
CytRx Corporation to Present at Upcoming Investor Conferences
LOS ANGELES , Nov. 27, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO, Steven ...
- ACCESSWIRE•5 months ago
Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx Corporation
NEW YORK, NY / ACCESSWIRE / November 20, 2017 / Eleven Biotherapeutics shares moved higher on Friday as investors continued to cheer the company's update last week in its earnings call about its Vicinium ...
- PR Newswire•5 months ago
CytRx Corporation Regains Nasdaq Listing Compliance
LOS ANGELES, Nov. 17, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it received written notification on November 16, 2017, from the NASDAQ Listing Qualifications Department that it has regained compliance with the minimum bid price requirement set forth in NASDAQ Listing Rule Section 5550(a)(2) for continued listing of its common stock on The NASDAQ Capital Market. Separately, CytRx has engaged the services of a third party firm to conduct an in-depth investigation to determine the extent of short-selling (both institutional and naked) in the Company's common stock. The investigation firm will also look into the possible intent to manipulate the value of CytRx shares, including information concerning erroneous statements from bloggers, postings to CytRx message boards and other questionable practices.
